{
    "info": {
        "nct_id": "NCT03746041",
        "official_title": "A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes",
        "inclusion_criteria": "* Age equal to or greater than 18\n* Patients must have a documented diagnosis of MDS or non-proliferative chronic myelomonocytic leukemia (CMML) (WBC < 12,000/mcL) according to World Health Organization (WHO) criteria (27)\n* Patients can be treatment-naïve or have received prior MDS-directed chemotherapy.\n\n  * Treatment-naïve MDS patients (or those previously treated with growth factors alone) must have Revised International Prognostic Scoring System (IPSS-R) categories of Very Low-, Low- or Intermediate-risk disease (see Appendix A for Revised International Prognostic Scoring System for MDS).\n  * MDS patients previously treated with disease-modifying chemotherapy (i.e. azacitidine, decitabine, lenalidomide, intensive chemotherapy, and/or an investigational agent) are eligible irrespective of IPSS-R score.\n* Patients must be off all non-transfusion therapy for MDS for 28 days prior to initiation of study treatment, including all types of growth factors.\n* Bone marrow biopsy (BMBx) within 30 days prior to first study treatment.\n* Cytopenia involving at least one cell line such as anemia, thrombocytopenia or leukopenia at the time of study enrollment. Cytopenias should be present on at least 2 different blood draws within 8 weeks of study enrollment. Definitions of cytopenias for the purposes of this study are as follows:\n\n  * Anemia: Patients must be symptomatic in the opinion of the treating physician with a hemoglobin ≤ 10.0 g/dL\n  * Thrombocytopenia: Platelet count < 100,000/microliter\n  * Neutropenia: Absolute neutrophil count < 1000/microliter\n* ECOG Performance Status 0-2\n* Adequate organ function as evidenced by:\n\n  * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × the upper limit of normal (ULN).\n  * Total bilirubin ≤2 mg/dL\n  * Serum creatinine <2 mg/dL, or creatinine clearance (calculated by the Cockcroft-Gault formula) ≤1.5 × ULN.\n* Urine dipstick for proteinuria < 2+. Patients discovered to have ≥ 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate ≤ 1 g of protein in 24 hours\n* International normalised ratio (INR) ≤1.5 and prothrombin time (PT) ≤ 1.5 x ULN\n* Women with an intact uterus (unless amenorrheic for the last 24 months) must have a negative serum pregnancy test within 30 days prior to enrollment into the study.\n* Females of childbearing potential and sexually active males must use effective contraception during the trial and for 6 months after the last dose of bevacizumab.\n* Written informed consent.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Bone marrow blasts equal to or greater than 20%\n* Patients actively receiving either abaloparatide, teriparatide or bisphosphonate therapy for other indications\n* Cumulative prior use of abaloparatide and/or any other parathyroid hormone analogs for > 20 months\n* History of allogeneic stem cell transplant\n* Pregnant or breast feeding female subjects\n* Platelets < 50,000/mm3\n* Major surgery (including open biopsy), significant traumatic injury within 28 days prior to enrollment or anticipation of the need for major surgery during study treatment\n* Prior malignancy (excluding localized cervical carcinoma or cutaneous basal cell/squamous cell carcinoma) unless in remission for at least 2 years.\n* Concurrent malignancy (excluding localized cervical carcinoma or cutaneous basal cell/squamous cell carcinoma)\n* Need for aspirin at a dose of ≥ 325 mg/day; if aspirin can be safely stopped or dose dropped to < 325 mg/day ≥ 10 days before the first dose of bevacizumab, then patient will remain eligible\n* Uncontrolled hypertension (blood pressures: systolic > 150 mmHg and/or diastolic > 100 mmHg)\n* Clinically significant cardiovascular disease present ≤6 months before enrollment as judged by the treating physician. Examples include:\n\n  1. Myocardial infarction\n  2. Unstable angina\n  3. Congestive heart failure NYHA Class ≥ II\n  4. Serious cardiac arrhythmia\n  5. Cerebrovascular accident and/or transient ischemic attack\n  6. Severe peripheral vascular disease (ischemic rest pain, non-healing wound or ulcer, or tissue loss)\n* Pulmonary embolus, deep venous thrombosis, or arterial thrombosis currently requiring anticoagulation\n* < 10 days since prior anticoagulants\n* Non-healing wound, active peptic ulcer or bone fracture\n* History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months of enrollment\n* Clinically significant hemorrhagic illness within the past 3 weeks\n* History of osteosarcoma\n* History of hyperparathyroidism\n* Elevated (>ULN) serum calcium level\n* Patients at increased risk for osteosarcoma, including those with Paget's disease of bone, unexplained elevations of alkaline phosphatase, and/or prior external beam or implant radiation therapy involving the skeleton.\n* Psychiatric illness or social situation that would preclude study compliance\n* Patients unable to give informed consent or to be followed up adequately\n* Known hypersensitivity to a product from Chinese Hamster Ovary mammalian cell or to a recombinant humanized monoclonal antibody\n* Other investigational treatments within 28 days of the start of study therapy",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Patients must have a documented diagnosis of MDS or non-proliferative chronic myelomonocytic leukemia (CMML) (WBC < 12,000/mcL) according to World Health Organization (WHO) criteria (27)",
            "criterions": [
                {
                    "exact_snippets": "documented diagnosis of MDS",
                    "criterion": "myelodysplastic syndrome (MDS) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "non-proliferative chronic myelomonocytic leukemia (CMML) (WBC < 12,000/mcL)",
                    "criterion": "chronic myelomonocytic leukemia (CMML) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "proliferative status",
                            "expected_value": "non-proliferative"
                        },
                        {
                            "requirement_type": "white blood cell count",
                            "expected_value": {
                                "operator": "<",
                                "value": 12000,
                                "unit": "mcL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "according to World Health Organization (WHO) criteria",
                    "criterion": "diagnosis according to WHO criteria",
                    "requirements": [
                        {
                            "requirement_type": "diagnostic standard",
                            "expected_value": "WHO criteria"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients can be treatment-naïve or have received prior MDS-directed chemotherapy.",
            "criterions": [
                {
                    "exact_snippets": "Patients can be treatment-naïve or have received prior MDS-directed chemotherapy.",
                    "criterion": "prior MDS-directed chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": [
                                "treatment-naïve",
                                "received prior MDS-directed chemotherapy"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment-naïve MDS patients (or those previously treated with growth factors alone) must have Revised International Prognostic Scoring System (IPSS-R) categories of Very Low-, Low- or Intermediate-risk disease (see Appendix A for Revised International Prognostic Scoring System for MDS).",
            "criterions": [
                {
                    "exact_snippets": "Treatment-naïve MDS patients (or those previously treated with growth factors alone)",
                    "criterion": "prior MDS treatment",
                    "requirements": [
                        {
                            "requirement_type": "treatment history",
                            "expected_value": [
                                "treatment-naïve",
                                "previously treated with growth factors alone"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "must have Revised International Prognostic Scoring System (IPSS-R) categories of Very Low-, Low- or Intermediate-risk disease",
                    "criterion": "IPSS-R risk category",
                    "requirements": [
                        {
                            "requirement_type": "category",
                            "expected_value": [
                                "Very Low",
                                "Low",
                                "Intermediate"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* MDS patients previously treated with disease-modifying chemotherapy (i.e. azacitidine, decitabine, lenalidomide, intensive chemotherapy, and/or an investigational agent) are eligible irrespective of IPSS-R score.",
            "criterions": [
                {
                    "exact_snippets": "MDS patients previously treated with disease-modifying chemotherapy (i.e. azacitidine, decitabine, lenalidomide, intensive chemotherapy, and/or an investigational agent)",
                    "criterion": "prior treatment with disease-modifying chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "treatment history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "chemotherapy agents",
                            "expected_value": [
                                "azacitidine",
                                "decitabine",
                                "lenalidomide",
                                "intensive chemotherapy",
                                "investigational agent"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "MDS patients",
                    "criterion": "diagnosis of MDS",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must be off all non-transfusion therapy for MDS for 28 days prior to initiation of study treatment, including all types of growth factors.",
            "criterions": [
                {
                    "exact_snippets": "off all non-transfusion therapy for MDS for 28 days prior to initiation of study treatment",
                    "criterion": "non-transfusion therapy for MDS",
                    "requirements": [
                        {
                            "requirement_type": "discontinuation duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "including all types of growth factors",
                    "criterion": "growth factor therapy",
                    "requirements": [
                        {
                            "requirement_type": "discontinuation duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Bone marrow biopsy (BMBx) within 30 days prior to first study treatment.",
            "criterions": [
                {
                    "exact_snippets": "Bone marrow biopsy (BMBx) within 30 days prior to first study treatment.",
                    "criterion": "bone marrow biopsy",
                    "requirements": [
                        {
                            "requirement_type": "performed_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days prior to first study treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age equal to or greater than 18",
            "criterions": [
                {
                    "exact_snippets": "Age equal to or greater than 18",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 18,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cytopenia involving at least one cell line such as anemia, thrombocytopenia or leukopenia at the time of study enrollment. Cytopenias should be present on at least 2 different blood draws within 8 weeks of study enrollment. Definitions of cytopenias for the purposes of this study are as follows:",
            "criterions": [
                {
                    "exact_snippets": "Cytopenia involving at least one cell line such as anemia, thrombocytopenia or leukopenia at the time of study enrollment",
                    "criterion": "cytopenia (anemia, thrombocytopenia, or leukopenia)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "cell line involvement",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "cell line"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at the time of study enrollment"
                        }
                    ]
                },
                {
                    "exact_snippets": "Cytopenias should be present on at least 2 different blood draws within 8 weeks of study enrollment",
                    "criterion": "cytopenia (anemia, thrombocytopenia, or leukopenia)",
                    "requirements": [
                        {
                            "requirement_type": "number of blood draws",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "blood draws"
                            }
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": "within 8 weeks of study enrollment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Thrombocytopenia: Platelet count < 100,000/microliter",
            "criterions": [
                {
                    "exact_snippets": "Thrombocytopenia: Platelet count < 100,000/microliter",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 100000,
                                "unit": "microliter"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Anemia: Patients must be symptomatic in the opinion of the treating physician with a hemoglobin ≤ 10.0 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Anemia: Patients must be symptomatic in the opinion of the treating physician",
                    "criterion": "anemia symptoms",
                    "requirements": [
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hemoglobin ≤ 10.0 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10.0,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Neutropenia: Absolute neutrophil count < 1000/microliter",
            "criterions": [
                {
                    "exact_snippets": "Neutropenia: Absolute neutrophil count < 1000/microliter",
                    "criterion": "absolute neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1000,
                                "unit": "microliter"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ECOG Performance Status 0-2",
            "criterions": [
                {
                    "exact_snippets": "ECOG Performance Status 0-2",
                    "criterion": "ECOG Performance Status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate organ function as evidenced by:",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × the upper limit of normal (ULN).",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase (AST) ... ≤2.5 × the upper limit of normal (ULN)",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine aminotransferase (ALT) ≤2.5 × the upper limit of normal (ULN)",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total bilirubin ≤2 mg/dL",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin ≤2 mg/dL",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum creatinine <2 mg/dL, or creatinine clearance (calculated by the Cockcroft-Gault formula) ≤1.5 × ULN.",
            "criterions": [
                {
                    "exact_snippets": "Serum creatinine <2 mg/dL",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "creatinine clearance (calculated by the Cockcroft-Gault formula) ≤1.5 × ULN",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* International normalised ratio (INR) ≤1.5 and prothrombin time (PT) ≤ 1.5 x ULN",
            "criterions": [
                {
                    "exact_snippets": "International normalised ratio (INR) ≤1.5",
                    "criterion": "International normalised ratio (INR)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": ""
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "prothrombin time (PT) ≤ 1.5 x ULN",
                    "criterion": "prothrombin time (PT)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women with an intact uterus (unless amenorrheic for the last 24 months) must have a negative serum pregnancy test within 30 days prior to enrollment into the study.",
            "criterions": [
                {
                    "exact_snippets": "Women with an intact uterus (unless amenorrheic for the last 24 months)",
                    "criterion": "uterus status",
                    "requirements": [
                        {
                            "requirement_type": "intact",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unless amenorrheic for the last 24 months",
                    "criterion": "amenorrhea duration",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 24,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "must have a negative serum pregnancy test within 30 days prior to enrollment into the study",
                    "criterion": "serum pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "time before enrollment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Written informed consent.",
            "criterions": [
                {
                    "exact_snippets": "Written informed consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "written",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "provided",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Females of childbearing potential and sexually active males must use effective contraception during the trial and for 6 months after the last dose of bevacizumab.",
            "criterions": [
                {
                    "exact_snippets": "Females of childbearing potential ... must use effective contraception during the trial and for 6 months after the last dose of bevacizumab.",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "usage",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "during the trial and for 6 months after the last dose of bevacizumab"
                        }
                    ]
                },
                {
                    "exact_snippets": "Females of childbearing potential",
                    "criterion": "female childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "sexually active males ... must use effective contraception during the trial and for 6 months after the last dose of bevacizumab.",
                    "criterion": "contraception use (males)",
                    "requirements": [
                        {
                            "requirement_type": "usage",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "during the trial and for 6 months after the last dose of bevacizumab"
                        }
                    ]
                },
                {
                    "exact_snippets": "sexually active males",
                    "criterion": "male sexual activity",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Urine dipstick for proteinuria < 2+. Patients discovered to have ≥ 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate ≤ 1 g of protein in 24 hours",
            "criterions": [
                {
                    "exact_snippets": "Urine dipstick for proteinuria < 2+",
                    "criterion": "proteinuria (urine dipstick)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2,
                                "unit": "+"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients discovered to have ≥ 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate ≤ 1 g of protein in 24 hours",
                    "criterion": "proteinuria (24 hour urine collection)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "g/24h"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Bone marrow blasts equal to or greater than 20%",
            "criterions": [
                {
                    "exact_snippets": "Bone marrow blasts equal to or greater than 20%",
                    "criterion": "bone marrow blasts",
                    "requirements": [
                        {
                            "requirement_type": "percentage",
                            "expected_value": {
                                "operator": ">=",
                                "value": 20,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of allogeneic stem cell transplant",
            "criterions": [
                {
                    "exact_snippets": "History of allogeneic stem cell transplant",
                    "criterion": "allogeneic stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of osteosarcoma",
            "criterions": [
                {
                    "exact_snippets": "History of osteosarcoma",
                    "criterion": "osteosarcoma",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnant or breast feeding female subjects",
            "criterions": [
                {
                    "exact_snippets": "Pregnant ... female subjects",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "breast feeding female subjects",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Psychiatric illness or social situation that would preclude study compliance",
            "criterions": [
                {
                    "exact_snippets": "Psychiatric illness ... would preclude study compliance",
                    "criterion": "psychiatric illness",
                    "requirements": [
                        {
                            "requirement_type": "impact on study compliance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "social situation that would preclude study compliance",
                    "criterion": "social situation",
                    "requirements": [
                        {
                            "requirement_type": "impact on study compliance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Myocardial infarction",
            "criterions": [
                {
                    "exact_snippets": "Myocardial infarction",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelets < 50,000/mm3",
            "criterions": [
                {
                    "exact_snippets": "Platelets < 50,000/mm3",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 50000,
                                "unit": "mm3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Other investigational treatments within 28 days of the start of study therapy",
            "criterions": [
                {
                    "exact_snippets": "Other investigational treatments within 28 days of the start of study therapy",
                    "criterion": "other investigational treatments",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Clinically significant hemorrhagic illness within the past 3 weeks",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant hemorrhagic illness within the past 3 weeks",
                    "criterion": "hemorrhagic illness",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "clinically significant"
                        },
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of hyperparathyroidism",
            "criterions": [
                {
                    "exact_snippets": "History of hyperparathyroidism",
                    "criterion": "hyperparathyroidism",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known hypersensitivity to a product from Chinese Hamster Ovary mammalian cell or to a recombinant humanized monoclonal antibody",
            "criterions": [
                {
                    "exact_snippets": "Known hypersensitivity to a product from Chinese Hamster Ovary mammalian cell",
                    "criterion": "hypersensitivity to a product from Chinese Hamster Ovary mammalian cell",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known hypersensitivity ... to a recombinant humanized monoclonal antibody",
                    "criterion": "hypersensitivity to a recombinant humanized monoclonal antibody",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled hypertension (blood pressures: systolic > 150 mmHg and/or diastolic > 100 mmHg)",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled hypertension",
                    "criterion": "hypertension",
                    "requirements": [
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "blood pressures: systolic > 150 mmHg",
                    "criterion": "systolic blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 150,
                                "unit": "mmHg"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "blood pressures: ... diastolic > 100 mmHg",
                    "criterion": "diastolic blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 100,
                                "unit": "mmHg"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Concurrent malignancy (excluding localized cervical carcinoma or cutaneous basal cell/squamous cell carcinoma)",
            "criterions": [
                {
                    "exact_snippets": "Concurrent malignancy (excluding localized cervical carcinoma or cutaneous basal cell/squamous cell carcinoma)",
                    "criterion": "concurrent malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": {
                                "operator": "!=",
                                "value": 0,
                                "unit": "localized cervical carcinoma or cutaneous basal cell/squamous cell carcinoma"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months of enrollment",
            "criterions": [
                {
                    "exact_snippets": "History of abdominal fistula ... within 6 months of enrollment",
                    "criterion": "abdominal fistula",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... gastrointestinal perforation ... within 6 months of enrollment",
                    "criterion": "gastrointestinal perforation",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... intra-abdominal abscess within 6 months of enrollment",
                    "criterion": "intra-abdominal abscess",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients actively receiving either abaloparatide, teriparatide or bisphosphonate therapy for other indications",
            "criterions": [
                {
                    "exact_snippets": "Patients actively receiving ... abaloparatide ... for other indications",
                    "criterion": "abaloparatide therapy",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "indication",
                            "expected_value": "other"
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients actively receiving ... teriparatide ... for other indications",
                    "criterion": "teriparatide therapy",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "indication",
                            "expected_value": "other"
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients actively receiving ... bisphosphonate therapy for other indications",
                    "criterion": "bisphosphonate therapy",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "indication",
                            "expected_value": "other"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Clinically significant cardiovascular disease present ≤6 months before enrollment as judged by the treating physician. Examples include:",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant cardiovascular disease present ≤6 months before enrollment as judged by the treating physician",
                    "criterion": "clinically significant cardiovascular disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "physician judgment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pulmonary embolus, deep venous thrombosis, or arterial thrombosis currently requiring anticoagulation",
            "criterions": [
                {
                    "exact_snippets": "Pulmonary embolus ... currently requiring anticoagulation",
                    "criterion": "pulmonary embolus",
                    "requirements": [
                        {
                            "requirement_type": "current anticoagulation requirement",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "deep venous thrombosis ... currently requiring anticoagulation",
                    "criterion": "deep venous thrombosis",
                    "requirements": [
                        {
                            "requirement_type": "current anticoagulation requirement",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "arterial thrombosis currently requiring anticoagulation",
                    "criterion": "arterial thrombosis",
                    "requirements": [
                        {
                            "requirement_type": "current anticoagulation requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior malignancy (excluding localized cervical carcinoma or cutaneous basal cell/squamous cell carcinoma) unless in remission for at least 2 years.",
            "criterions": [
                {
                    "exact_snippets": "Prior malignancy (excluding localized cervical carcinoma or cutaneous basal cell/squamous cell carcinoma) unless in remission for at least 2 years.",
                    "criterion": "prior malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": [
                                "localized cervical carcinoma",
                                "cutaneous basal cell carcinoma",
                                "cutaneous squamous cell carcinoma"
                            ]
                        },
                        {
                            "requirement_type": "remission_duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Unstable angina",
            "criterions": [
                {
                    "exact_snippets": "Unstable angina",
                    "criterion": "unstable angina",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Cerebrovascular accident and/or transient ischemic attack",
            "criterions": [
                {
                    "exact_snippets": "Cerebrovascular accident",
                    "criterion": "cerebrovascular accident",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "transient ischemic attack",
                    "criterion": "transient ischemic attack",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Elevated (>ULN) serum calcium level",
            "criterions": [
                {
                    "exact_snippets": "Elevated (>ULN) serum calcium level",
                    "criterion": "serum calcium level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cumulative prior use of abaloparatide and/or any other parathyroid hormone analogs for > 20 months",
            "criterions": [
                {
                    "exact_snippets": "Cumulative prior use of abaloparatide and/or any other parathyroid hormone analogs for > 20 months",
                    "criterion": "cumulative prior use of abaloparatide",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 20,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Cumulative prior use of ... any other parathyroid hormone analogs for > 20 months",
                    "criterion": "cumulative prior use of any other parathyroid hormone analogs",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 20,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* < 10 days since prior anticoagulants",
            "criterions": [
                {
                    "exact_snippets": "< 10 days since prior anticoagulants",
                    "criterion": "time since prior anticoagulant use",
                    "requirements": [
                        {
                            "requirement_type": "time since prior use",
                            "expected_value": {
                                "operator": "<",
                                "value": 10,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgery (including open biopsy), significant traumatic injury within 28 days prior to enrollment or anticipation of the need for major surgery during study treatment",
            "criterions": [
                {
                    "exact_snippets": "Major surgery (including open biopsy), significant traumatic injury within 28 days prior to enrollment",
                    "criterion": "major surgery or significant traumatic injury",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to enrollment"
                        }
                    ]
                },
                {
                    "exact_snippets": "anticipation of the need for major surgery during study treatment",
                    "criterion": "anticipated need for major surgery",
                    "requirements": [
                        {
                            "requirement_type": "anticipated need",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "during study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients unable to give informed consent or to be followed up adequately",
            "criterions": [
                {
                    "exact_snippets": "Patients unable to give informed consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "ability to give consent",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unable ... to be followed up adequately",
                    "criterion": "follow-up ability",
                    "requirements": [
                        {
                            "requirement_type": "ability to be followed up adequately",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Congestive heart failure NYHA Class ≥ II",
            "criterions": [
                {
                    "exact_snippets": "Congestive heart failure NYHA Class ≥ II",
                    "criterion": "congestive heart failure NYHA class",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "NYHA class"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Non-healing wound, active peptic ulcer or bone fracture",
            "criterions": [
                {
                    "exact_snippets": "Non-healing wound",
                    "criterion": "wound",
                    "requirements": [
                        {
                            "requirement_type": "healing status",
                            "expected_value": "non-healing"
                        }
                    ]
                },
                {
                    "exact_snippets": "active peptic ulcer",
                    "criterion": "peptic ulcer",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "bone fracture",
                    "criterion": "bone fracture",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Severe peripheral vascular disease (ischemic rest pain, non-healing wound or ulcer, or tissue loss)",
            "criterions": [
                {
                    "exact_snippets": "Severe peripheral vascular disease",
                    "criterion": "peripheral vascular disease",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                },
                {
                    "exact_snippets": "ischemic rest pain",
                    "criterion": "ischemic rest pain",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "non-healing wound or ulcer",
                    "criterion": "non-healing wound or ulcer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "tissue loss",
                    "criterion": "tissue loss",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Need for aspirin at a dose of ≥ 325 mg/day; if aspirin can be safely stopped or dose dropped to < 325 mg/day ≥ 10 days before the first dose of bevacizumab, then patient will remain eligible",
            "criterions": [
                {
                    "exact_snippets": "Need for aspirin at a dose of ≥ 325 mg/day",
                    "criterion": "aspirin use",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 325,
                                "unit": "mg/day"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "if aspirin can be safely stopped or dose dropped to < 325 mg/day ≥ 10 days before the first dose of bevacizumab",
                    "criterion": "aspirin use",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": "<",
                                "value": 325,
                                "unit": "mg/day"
                            }
                        },
                        {
                            "requirement_type": "timing before bevacizumab",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Serious cardiac arrhythmia",
            "criterions": [
                {
                    "exact_snippets": "Serious cardiac arrhythmia",
                    "criterion": "cardiac arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "serious"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients at increased risk for osteosarcoma, including those with Paget's disease of bone, unexplained elevations of alkaline phosphatase, and/or prior external beam or implant radiation therapy involving the skeleton.",
            "criterions": [
                {
                    "exact_snippets": "increased risk for osteosarcoma",
                    "criterion": "risk for osteosarcoma",
                    "requirements": [
                        {
                            "requirement_type": "risk level",
                            "expected_value": "increased"
                        }
                    ]
                },
                {
                    "exact_snippets": "Paget's disease of bone",
                    "criterion": "Paget's disease of bone",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unexplained elevations of alkaline phosphatase",
                    "criterion": "alkaline phosphatase",
                    "requirements": [
                        {
                            "requirement_type": "elevation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "cause",
                            "expected_value": "unexplained"
                        }
                    ]
                },
                {
                    "exact_snippets": "prior external beam or implant radiation therapy involving the skeleton",
                    "criterion": "prior radiation therapy involving the skeleton",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}